AlphaQuest LLC Sells 3,869 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

AlphaQuest LLC reduced its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 50.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 3,860 shares of the specialty pharmaceutical company’s stock after selling 3,869 shares during the period. AlphaQuest LLC’s holdings in Supernus Pharmaceuticals were worth $140,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its holdings in Supernus Pharmaceuticals by 29.9% in the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Geode Capital Management LLC raised its holdings in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company’s stock worth $27,242,000 after acquiring an additional 40,968 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Supernus Pharmaceuticals by 1.1% in the 3rd quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after acquiring an additional 7,833 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Supernus Pharmaceuticals by 7.3% in the 4th quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company’s stock worth $14,449,000 after acquiring an additional 27,134 shares during the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total transaction of $27,734.00. Following the completion of the sale, the vice president now owns 10,149 shares of the company’s stock, valued at $402,103.38. The trade was a 6.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,104 shares of company stock worth $440,263. Insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Trading Up 2.9 %

Shares of SUPN opened at $32.16 on Tuesday. The firm has a market cap of $1.79 billion, a PE ratio of 30.06 and a beta of 0.83. The firm has a fifty day simple moving average of $36.13 and a two-hundred day simple moving average of $35.15. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SUPN shares. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.